Merck & Co (NY:MRK)

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Topics Economy Intellectual Property

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

Today 10:12 EST

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

Topics Artificial Intelligence Economy Intellectual Property

Today 10:05 EST

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

Today 10:04 EST

Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025

Topics Artificial Intelligence Economy Intellectual Property

December 24, 2025

As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D...

Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery

Topics Bonds Earnings World Trade

December 24, 2025

As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

Topics Initial Public Offering

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...

Topics Artificial Intelligence Economy Intellectual Property

Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition

December 24, 2025

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...

Topics Economy

Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring

December 24, 2025

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

Topics Intellectual Property

Top 5 US Healthcare Stocks By Market Value ↗

December 24, 2025

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Topics Government

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency

Topics Economy

SCHD vs. NOBL: Different Paths to Dividend Stability ↗

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Topics ETFs

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Topics ETFs Economy Intellectual Property

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Topics Economy Intellectual Property

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

This year has been one to forget for these pharmaceutical giants.

Topics Earnings Initial Public Offering Intellectual Property

Better Buy in 2026: Pfizer or Merck? ↗

December 19, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics Intellectual Property

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Topics Government World Trade

December 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck & Co. Inc. (NYSE:MRK) Stands Out as a Durable Dividend Stock ↗

December 19, 2025

Merck (MRK) offers a strong 3.43% dividend yield, backed by a history of increases, high profitability, and solid financial health for durable income.

Via Chartmill

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

Topics Economy Government

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition...

Topics Artificial Intelligence ETFs Economy

The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'

December 18, 2025

Merck Scores FDA Fast-Track Review For Key Cholesterol And Cancer Drugs With Multibillion-Dollar Potential: Report ↗

Topics Artificial Intelligence Economy World Trade

December 17, 2025

While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide decanoate, the other is its cancer therapy Sacituzumab tirumotecan.

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Topics Government World Trade

The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗

December 17, 2025

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Topics Intellectual Property

December 17, 2025

From Merck & Co., Inc.

Via Business Wire

Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast ↗

December 16, 2025

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.

New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall...

Topics Intellectual Property Stocks

Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector

December 16, 2025

Each company has a bullish case, but three stand out as great long-term buys.

Topics Intellectual Property

Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗

December 16, 2025